<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00871182</url>
  </required_header>
  <id_info>
    <org_study_id>PT0010801</org_study_id>
    <nct_id>NCT00871182</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Efficacy of Inhaled PT001 in Patients With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>A Randomized, Double-blind, Single Dose, Four-period, Six-treatment, Placebo-controlled, Balanced, Incomplete Block, Cross-over, Study of Four Doses of Inhaled PT001 in Patients With Mild to Moderate COPD, Compared to Open Label Tiotropium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pearl Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pearl Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of inhaled PT001 compared to&#xD;
      placebo and tiotropium in patients with mild to moderate chronic obstructive pulmonary&#xD;
      disease (COPD).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak improvement in forced expiratory volume in one second (FEV1)</measure>
    <time_frame>Day 1</time_frame>
    <description>Day 1 serial FEV1 measured over 24 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to onset of action (&gt;10% improvement in FEV1 from baseline)</measure>
    <time_frame>Day 1</time_frame>
    <description>Day 1 serial FEV1 measured over 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to peak FEV1</measure>
    <time_frame>Day 1</time_frame>
    <description>Day 1 serial FEV1 measured over 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 area under the curve (AUC) from 0 to 24 hours</measure>
    <time_frame>Day 1</time_frame>
    <description>Day 1 serial FEV1 measured over 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC from 0 to 12 hours</measure>
    <time_frame>Day 1</time_frame>
    <description>Day 1 serial FEV1 measured over 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1 at 12 and 24 hours</measure>
    <time_frame>Day 1</time_frame>
    <description>Day 1 serial FEV1 measured over 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Improvement in inspiratory capacity (IC)</measure>
    <time_frame>Day 1</time_frame>
    <description>Day 1 serial IC measured over 24 hours</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>PT001 18 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled PT001 18 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PT001 36 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled PT001 36 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PT001 72 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled PT001 72 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PT001 144 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled PT001 144 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhaled Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inhaled Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium Handihaler</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tiotropium 18 mcg administered via Handihaler</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled PT001</intervention_name>
    <description>single dose, inhaled</description>
    <arm_group_label>PT001 144 mcg</arm_group_label>
    <arm_group_label>PT001 18 mcg</arm_group_label>
    <arm_group_label>PT001 36 mcg</arm_group_label>
    <arm_group_label>PT001 72 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled Placebo</intervention_name>
    <description>single dose, inhaled</description>
    <arm_group_label>Inhaled Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium Handihaler</intervention_name>
    <description>single dose, tiotropium 18 mcg administered via the Handihaler</description>
    <arm_group_label>Tiotropium Handihaler</arm_group_label>
    <other_name>Spiriva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
          -  40 - 75 years of age&#xD;
&#xD;
          -  Females of non-child bearing potential or females of child bearing potential with&#xD;
             negative pregnancy test; and acceptable contraceptive methods&#xD;
&#xD;
          -  COPD diagnosis&#xD;
&#xD;
          -  Current/former smokers with at least a 10 pack-year history of cigarette smoking&#xD;
&#xD;
          -  Patients with established clinical history of COPD and severity defined as a&#xD;
             post-ipratropium FEV1/FVC ratio of ≤0.70 and FEV1 ≥50 and ≤85% of predicted normal at&#xD;
             Screening&#xD;
&#xD;
          -  Must demonstrate reversibility to ipratropium demonstrated by a &gt;200 mL improvement&#xD;
             over baseline and/or &gt;12% and &gt;150 mL improvement over baseline&#xD;
&#xD;
          -  Patients willing to stay at study site for at least 24 hours on each test day&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are pregnant or lactating&#xD;
&#xD;
          -  Primary diagnosis of asthma&#xD;
&#xD;
          -  Alpha-1 antitrypsin deficiency as the cause of COPD&#xD;
&#xD;
          -  Active pulmonary diseases&#xD;
&#xD;
          -  Prior lung volume reduction surgery&#xD;
&#xD;
          -  Abnormal chest X-ray (or CT scan) not due to the presence of COPD&#xD;
&#xD;
          -  Hospitalized due to poorly controlled COPD within 24 weeks of Screening&#xD;
&#xD;
          -  Unable to perform acceptable spirometry&#xD;
&#xD;
          -  Poorly controlled COPD in prior 6-weeks, defined as the occurrence of acute worsening&#xD;
             of COPD requiring corticosteroids or antibiotics or acute worsening of COPD requiring&#xD;
             treatment prescribed by a physician&#xD;
&#xD;
          -  Clinically significant medical conditions&#xD;
&#xD;
          -  Symptomatic prostatic hypertrophy or bladder neck obstruction&#xD;
&#xD;
          -  Known narrow-angle glaucoma&#xD;
&#xD;
          -  Lower respiratory tract infection requiring antibiotics in past 6 weeks&#xD;
&#xD;
          -  Clinically significant abnormal ECG&#xD;
&#xD;
          -  Clinically significant uncontrolled hypertension&#xD;
&#xD;
          -  Positive Hepatitis B surface antigen or Hepatitis C antibody&#xD;
&#xD;
          -  Cancer that has not been in complete remission for at least 5 years&#xD;
&#xD;
          -  History of hypersensitivity to any beta2-agonists or anticholinergics&#xD;
&#xD;
          -  History of severe milk protein allergy&#xD;
&#xD;
          -  Known or suspected history of alcohol or drug abuse&#xD;
&#xD;
          -  Medically unable to withhold short acting bronchodilators for 6-hours&#xD;
&#xD;
          -  Use of the medications below in specified time interval prior to Screening: 3 months:&#xD;
             depot corticosteroids, intra-articular corticosteroids; 6 weeks: oral corticosteroids,&#xD;
             antibiotics administered for a COPD exacerbation; and 1 month: P-glycoprotein&#xD;
             inhibitors, CYP450 3A4 inhibitors, ICS &gt;1000 μg/day of fluticasone propionate or&#xD;
             equivalent&#xD;
&#xD;
          -  The following COPD medications need to be stopped and switched to appropriate&#xD;
             replacement therapies: tiotropium, oral beta2 agonists, LABAs, combination&#xD;
             corticosteroid/LABAs, theophylline, leukotriene inhibitors,cromoglycate and nedocromil&#xD;
&#xD;
          -  Use of the following medications is prohibited: tricyclic antidepressants, monoamine&#xD;
             oxidase (MAO) inhibitors, beta-adrenergic antagonists, anticonvulsants (barbiturates,&#xD;
             hydantoins, and carbamazepine and phenothiazines&#xD;
&#xD;
          -  Receiving long-term-oxygen or nocturnal oxygen therapy for &gt;12 hours a day&#xD;
&#xD;
          -  Diagnosis of sleep apnea that is uncontrolled&#xD;
&#xD;
          -  Participation in acute phase of pulmonary rehabilitation in prior 4 weeks&#xD;
&#xD;
          -  Will enter acute phase of pulmonary rehabilitation program during study&#xD;
&#xD;
          -  Unable to comply with study procedures&#xD;
&#xD;
          -  Affiliated with Investigator site&#xD;
&#xD;
          -  Questionable validity of consent&#xD;
&#xD;
          -  Use of investigational study drug/participation in clinical study in the last 30 days&#xD;
             or 5 half lives prior to Screening, whichever is longer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Colin Reisner, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Pearl Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pivotal Research Centers</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elite Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonary and Critical Care Medicine</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati VAMC</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spartanburg Medical Research</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>March 26, 2009</study_first_submitted>
  <study_first_submitted_qc>March 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2009</study_first_posted>
  <disposition_first_submitted>August 24, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>August 24, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 27, 2010</disposition_first_posted>
  <last_update_submitted>June 12, 2013</last_update_submitted>
  <last_update_submitted_qc>June 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>obstructive lung diseases</keyword>
  <keyword>Tiotropium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

